Todos os posts
Revisão | Estratégias de oxigenação após extubação de pacientes criticamente doentes e pós-cirúrgicos.
13 Ago, 2021 | 11:57hOpinião | Os médicos fazem juramento de não causar dano. Todo o setor de cuidado em saúde deveria fazer o mesmo na luta contra as mudanças climáticas.
13 Ago, 2021 | 11:56hIncidência e mortalidade globais do câncer gástrico, 1980-2018.
13 Ago, 2021 | 11:55hGlobal Incidence and Mortality of Gastric Cancer, 1980-2018 – JAMA Network Open
Estudo randomizado | Avaliação da vacina de mRNA da Moderna em adolescentes.
12 Ago, 2021 | 12:30hEvaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents – New England Journal of Medicine
Conteúdos relacionados:
Comentários no Twitter
The mRNA-1273 vaccine was effective in preventing #COVID19 in 12-to-17-year-olds. Immune response was similar to young adults. https://t.co/aC3Dmjqe2T pic.twitter.com/9RxgHApW29
— NEJM (@NEJM) August 11, 2021
The @moderna_tx covid vaccine trial in 3,732 teens, placebo-controlled, published today @NEJM with both excellent safety profile and efficacy vs covid, and immune response as least as good as young adults https://t.co/PVmhjwgwsU pic.twitter.com/3uCmteaWNx
— Eric Topol (@EricTopol) August 11, 2021
Estudo randomizado | Terceira dose da vacina de mRNA da Moderna aumenta a imunidade em receptores de transplantes.
12 Ago, 2021 | 12:28hEditorial: Third Time’s a Charm — Covid-19 Vaccine Hope for Solid-Organ Transplant Recipients
Conteúdos relacionados:
[Preprint] 3rd AstraZeneca shot gives strong immunity.
Comentários no Twitter
..1st randomized trial results of 3rd doses of Moderna vax for 120 people with organ transplants: month 4, their minimum anti-RBD antibody levels were 55% for 3rd dose vs 18% (still increasing a little in the placebo group). No cases of acute rejection https://t.co/BcfeyUEhx5 #IC
— Hilda Bastian, PhD (@hildabast) August 11, 2021
The authors conclude that a third-dose booster of mRNA-1273 vaccine should be considered for transplant recipients. https://t.co/Q3gakSaNjd pic.twitter.com/CMN8f7cq29
— NEJM (@NEJM) August 11, 2021
Vacina da Moderna pode ser superior à vacina da Pfizer contra a variante Delta.
12 Ago, 2021 | 12:25hModerna may be superior to Pfizer against delta variant — breakthrough odds rise with time – CNBC
Estudo original 1 (preprint): Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence – medRxiv
Estudo original 2 (preprint): Neutralizing antibody responses to SARS-CoV-2 variants in vaccinated Ontario long-term care home residents and workers – medRxiv
Conteúdo relacionado: Study shows AstraZeneca and Pfizer vaccines are effective against Delta variant, but both doses are needed.
[Preprint] Efetividade das vacinas da Pfizer vs. Moderna contra a variante Delta da COVID-19 no Catar – A efetividade contra doença sintomática causada pela variante Delta foi de 53,5% para a vacina da Pfizer e de 84,8% para a da Moderna; a efetividade contra doença grave pela mesma variante foi de 89,7% para Pfizer e de 100% para a Moderna.
12 Ago, 2021 | 12:23hConteúdo relacionado: Study shows AstraZeneca and Pfizer vaccines are effective against Delta variant, but both doses are needed.
Comentário no Twitter
New and important data on Delta breakthrough infections, large Qatar experience and follow-up of > 1.2 million vaccinees https://t.co/2ye1Kz9OPV
2-doses vaccine effectiveness vs infections
Pfizer 53.5%
Moderna 84.8%
Either 57.2%
(replicates gap of recent Mayo Clinic study) pic.twitter.com/ghWuWbYPLH— Eric Topol (@EricTopol) August 11, 2021
Características clínicas da trombocitopenia e da trombose imunes induzidas por vacina.
12 Ago, 2021 | 12:21hComentário: Largest Study of VITT After COVID-19 Vaccination Digs Into Lab, Clinical Features – TCTMD
Conteúdos relacionados:
NICE COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis.
Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.
Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (vários artigos e fontes sobre o tema)
Comentário no Twitter
The phenotypes of VITT were defined in 220 patients presenting a 14-day median after the first ChAdOx1 nCoV-19 dose. Mortality was 22%. https://t.co/ir0yG5X0BP #COVID19 #IDTwitter pic.twitter.com/iAfxs0I1Ce
— NEJM (@NEJM) August 11, 2021
Estudo clínico Solidarity da OMS entra em uma nova fase com 3 novas drogas candidatas.
12 Ago, 2021 | 12:18hComentário: WHO-led Trial Will Test Malaria and Cancer Medicines Against COVID-19 – Health Policy Watch
Conteúdos relacionados:
WHO Solidarity trial to restart with focus on drugs that act on immune responses caused by Covid-19.
Comentário no Twitter (fio – clique para saber mais)
WHO’s #COVID19 Solidarity clinical trial enters a new phase – Solidarity PLUS – with three new candidate drugs:
-artesunate
-imatinib
-infliximab— World Health Organization (WHO) (@WHO) August 11, 2021
Vacinação: Efetividade versus eficácia.
12 Ago, 2021 | 12:17hVaccination: Effectiveness versus Efficacy – by Luis Correa, MD